G
Gianfranco Fornasini
Researcher at Sigma-Tau
Publications - 13
Citations - 833
Gianfranco Fornasini is an academic researcher from Sigma-Tau. The author has contributed to research in topics: Carnitine & End stage renal disease. The author has an hindex of 8, co-authored 13 publications receiving 742 citations. Previous affiliations of Gianfranco Fornasini include University of South Australia.
Papers
More filters
Journal ArticleDOI
Pharmacokinetics of L-carnitine.
TL;DR: The renal clearance of L-carnitine increases after exogenous administration, approaching GFR after high intravenous doses, and many forms of secondary carnitine deficiency, including some drug-induced disorders, arise from impaired renal tubular re absorption.
Journal ArticleDOI
Accumulation of trimethylamine and trimethylamine- N -oxide in end-stage renal disease patients undergoing haemodialysis
TL;DR: TMA and TMNO accumulate between haemodialysis sessions in ESRD patients, but are efficiently removed during a single haemmodialysis session.
Journal ArticleDOI
Trimethylamine: metabolic, pharmacokinetic and safety aspects.
TL;DR: Trimethylaminuria is a condition that is characterized by a deficiency in FMO3 enzyme activity, resulting in the excretion of increased amounts of TMA in bodily fluids such as urine and sweat, and breath.
Journal ArticleDOI
Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis
Allan M. Evans,Randall Faull,Gianfranco Fornasini,Edward F. Lemanowicz,Antonio Longo,Silvia Pace,Roger L. Nation +6 more
TL;DR: Evaluated the pharmacokinetics of intravenous L‐carnitine in patients undergoing long‐term hemodialysis to find out if it can be administered to restore plasma and tissue levels.
Journal ArticleDOI
Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease.
Allan M. Evans,Randall J. Faull,Roger L. Nation,Shilpanjali Prasad,Tony J Elias,Stephanie E. Reuter,Gianfranco Fornasini +6 more
TL;DR: Long-term hemodialysis treatment is associated with a significant reduction in endogenous plasma and muscle L-c Carnitine levels and a significant increase in plasma acylcarnitines, while muscle levels continue to decline after 12 months of treatment.